Clinical trials
Completed Observational Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
67 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 67 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 11 |
| Bristol-Myers Squibb | 7 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 5 |
| Pfizer | 3 |
| University Hospital, Bordeaux | 2 |
| Ann & Robert H Lurie Children's Hospital of Chicago | 1 |
| Asan Medical Center | 1 |
| Assiut University | 1 |
| Brian Leber | 1 |
| Cepheid | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 67 |
| Leukemia, Myeloid, Acute | 8 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 |
| Myelodysplastic Syndromes | 6 |
| Leukemia | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
| Multiple Myeloma | 5 |
| Leukemia, Myeloid, Chronic-Phase | 4 |
| Lymphoma | 3 |
| Lymphoma, Non-Hodgkin | 3 |
Trials
Showing 1 to 25 of 67. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.